Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials

• Published in: OncoTargets and therapy Vol. 11; pp. 9049 - 9059
• Main Authors: Wei, Jinli, Luo, Yulin, Fu, Deyuan
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2018; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Adjuvant chemotherapy; Analysis; Antineoplastic agents; Bevacizumab; Bias; Breast cancer; Cancer therapies; Cancer treatment; Carboplatin; Care and treatment; Chemotherapy; Clinical trials; ErbB-2 protein; Hormones; Immunotherapy; Mastectomy; Meta-analysis; Metastasis; Monoclonal antibodies; Patient outcomes; Review; Studies; Survival; Systematic review; Targeted cancer therapy; bevacizumab; neoadjuvant chemotherapy; breast cancer; HER2-negative; randomized controlled trial

To better clarify the efficacy of neoadjuvant bevacizumab plus chemotherapy (BEV + CT) vs chemotherapy (CT) alone in the treatment of HER2-negative nonmetastatic breast cancer. PubMed, Embase, Web of Science, and Cochrane Library databases were searched for relevant articles published from January 1...